In 2014, ibrutinib was the first BTK inhibitor to gain Health Canada approval based on the RESONATE trial, which demonstrated superior progression-free survival (PFS) and overall survival (OS) compared to ofatumumab (an anti-CD20 monoclonal antibody) in patients with relapsed CLL [9]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.